Latest & greatest articles for covid-19

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on covid-19 or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on covid-19 and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for covid-19

1. Reducing the minimum age for mask wearing requirements and recommendations in COVID-19

Reducing the minimum age for mask wearing requirements and recommendations in COVID-19 Advice to the National Public Health Emergency Team: Reduction of the minimum age for the application of mask wearing requirements and recommendations - Update Health Information and Quality Authority Page 1 of 20 Advice to the National Public Health Emergency Team Reduction of the minimum age for the application of mask wearing requirements and recommendations – Update to advice submitted 3 March 2021 (...) and Quality Authority Page 3 of 20 Foreword The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious virus resulting in over 100 million cases and three million deaths since its emergence in 2019. In the context of the ongoing COVID-19 pandemic, SARS-CoV-2 constitutes a significant public health concern due to its high basic reproduction rate, the limited evidence of effective treatment approaches, and the constrained supply of vaccines in the early stages of population

2021 Health Information and Quality Authority

2. The need for safe, stable and sustainable resumption of planned surgery in an era of COVID?19

The need for safe, stable and sustainable resumption of planned surgery in an era of COVID?19 Editorial Theneedforsafe,stableandsustainableresumptionof plannedsurgeryinaneraofCOVID-19 J.Price, 1 T.Sheraton, 2 R.Self 3 andT.M.Cook 1 1Consultant,DepartmentofAnaesthesiaandIntensiveCare,RoyalUnitedHospitalFoundationTrust,Bath,UK 2Consultant,DepartmentofAnaesthesia,AneurinBevanUniversityHealthBoard,Newport,Gwent,Wales 3Consultant,DepartmentofAnaesthesia,TheRoyalMarsdenNHSFoundationTrust,London,UK (...) ?cantlydeleteriouseffect on surgical capacity. The Anaesthesia and Critical Care Covid-19 tracking (ACCC Track) survey [3] showed signi?cant disruption toperi-operative carein two-thirds of hospitals and severe disruption in one quarter. Compared with the corresponding period in 2019, one out of ?ve operatingtheatreswereclosedandinthosethatwereopen, activitywasmostcommonlyaround75%ofnormal.Almost two-thirdsofhospitalswereundertakingsurgeryatexternal sites,includingintheindependentsector.Therewasa30% decrease

2021 ICM Anaesthesia COVID-19

3. Covid-19 candidate vaccines (update)

). 2020. Available from: https://www.who.int/emergencies/diseases/novel- coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-coronaviruses. Accessed on 15 February 2021. 2. World Health Organization. Coronavirus Disease (COVID-19) Pandemic. 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed on 15 February 2021. 3. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270 (...) Covid-19 candidate vaccines (update) COVID-19 is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which responsible for the outbreak began in Wuhan, China, in December 2019 and progressively became pandemic affecting more than 120 countries globally. 1 As of 15 February 2020, confirmed cases of COVID-19 accumulated to 108 million people worldwide, with confirmed death cases of 2,381,295 people. 2 SARS-CoV-2 is highly transmissible and pathogenic virus

2021 MaHTAS Covid-19 Rapid Evidence Updates

4. Ad26.COV2.S (recombinant) Janssen COVID-19 Vaccine

Ad26.COV2.S (recombinant) Janssen COVID-19 Vaccine Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2021 Health Canada - Drug and Health Product Register

5. SARS-CoV-2 infection, COVID-19 and timing of elective surgery

. Public Health England. COVID-19 infection prevention and control guidance: transmission based precautions (TBPs). 2021. https://www.gov.uk/government/publications/wuhan-novel- coronavirus-infection-prevention-and-control/covid-19-infection-prevention-and-control- guidance-transmission-based-precautions-tbps. (accessed 18/02/2021) 28. Cook TM. Personal protective equipment during the coronavirus disease (COVID) 2019 pandemic – a narrative review. Anaesthesia 2020; 75: 920–927. 29. National Institute (...) SARS-CoV-2 infection, COVID-19 and timing of elective surgery SARS-CoV-2 infection, COVID-19 and timing of elective surgery A multidisciplinary consensus statement on behalf of the Association of Anaesthetists, Centre for Perioperative Care, Federation of Surgical Specialty Associations, Royal College of Anaesthetists, Royal College of Surgeons of England K. El-Boghdadly, 1,2 T. M. Cook, 3,4 T. Goodacre, 5,6 J. Kua, 7 L. Blake, 8 S. Denmark, 9 S. McNally, 10,11 N. Mercer, 12,13 S. R

2021 ICM Anaesthesia COVID-19

6. Healthcare personnel who do not avail of COVID-19 vaccination

Healthcare personnel who do not avail of COVID-19 vaccination Policies relating to healthcare personnel who do not avail of COVID-19 vaccination Health Information and Quality Authority Page 1 of 17 Advice to the National Public Health Emergency Team An international review: Policies relating to healthcare personnel who do not avail of COVID-19 vaccination Submitted to NPHET: 8 April 2021 Updated: 20 April 2021 Policies relating to healthcare personnel who do not avail of COVID-19 vaccination (...) - user experience surveys across a range of health services, in conjunction with the Department of Health and the HSE. Policies relating to healthcare personnel who do not avail of COVID-19 vaccination Health Information and Quality Authority Page 3 of 17 Version History Version number Date Details V1.0 14 April 2021 V2.0 20 April 2021 Removing HSE’s stipulation of 1 April 2021 that nursing and other healthcare students who are eligible for COVID-19 vaccination, but who have declined vaccination

2021 Health Information and Quality Authority

7. Lessons from COVID-19: Leveraging Integrated Care During Ontario’s COVID-19 Response

Lessons from COVID-19: Leveraging Integrated Care During Ontario’s COVID-19 Response EVIDENCE INSIGHT ACTION >> >> 8 JUNE 2017 Rapid Synthesis Lessons from COVID-19: Leveraging Integrated Care During Ontario’s COVID-19 Response 26 March 2021 HEALTH FORUMMcMaster Health Forum 1 Evidence >> Insight >> Action Rapid Synthesis: Lessons from COVID-19: Leveraging Integrated Care During Ontario’s COVID-19 Response 30-day response 26 March 2021 McMaster Health Forum 2 Evidence >> Insight >> Action Rapid (...) -19: Leveraging integrated care during Ontario’s COVID-19 response. Hamilton: McMaster Health Forum, 26 March 2021. Product registration numbers ISSN 2292-7999 (online)McMaster Health Forum 3 Evidence >> Insight >> Action KEY MESSAGES Questions 1. How have efforts towards integrated care in Ontario Health Teams intersected with responses to the pandemic? 2. What lessons have been learned to support pandemic responses and integrated care in Ontario going forward? Why the issue is important

2021 McMaster Health Forum

8. Clinical Features of the 60 Years and Older Patients Infected with 2019 Novel Coronavirus: Can We Predict Mortality Earlier?

Clinical Features of the 60 Years and Older Patients Infected with 2019 Novel Coronavirus: Can We Predict Mortality Earlier? Clinical Features of the 60 Years and Older Patients Infected with 2019 Novel Coronavirus: Can We Predict Mortality Earlier? - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 Information Show account (...) Kırdar City Hospital, University of Health Sciences, Istanbul, Turkey. PMID: 33784699 DOI: Item in Clipboard Full text links Cite Display options Display options Format Abstract Introduction: The novel coronavirus (COVID-19), which has affected over 100 countries in a short while, progresses more mortally in elderly patients with comorbidities. In this study, we examined the epidemiological, clinical, and laboratory characteristics of the patients aged 60 and over who had been infected with COVID-19

2021 EvidenceUpdates

9. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial Full Text available with Trip Pro

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 Information Show account info Close (...) RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Randomized Controlled Trial Nat Commun Actions . 2021 Mar 30;12(1):1967. doi: 10.1038/s41467-021-22177-1. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial , # , # , # , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Medicine, Stanford University, Stanford, CA, USA. prasj

2021 EvidenceUpdates

10. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial Full Text available with Trip Pro

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 Information Show account info Close Account Logged in as: username Search: Search Save Email Send to Display options Display options Format Save citation to file Format: Create file Cancel Email citation Subject: 1 selected item: 33754144 - PubMed To: Format: MeSH and other data Send email Cancel Add to Collections Create a new collection Add to an existing collection Name your collection

2021 EvidenceUpdates

11. Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice

Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice Global Navigation Other sites: European Centre for Disease Prevention and Control An agency of the European Union Main Navigation Secondary Navigation Search Search Search Search Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice Technical report 29 Mar 2021 (...) Cite: European Centre for Disease Prevention and Control Rollout of COVID-19 vaccines in the EU/EEA: challenges and good practice. 29 March 2021. Stockholm: ECDC; 2021. The aim of this report is to share the challenges countries are facing with the rollout of the COVID-19 vaccine deployment process. It also aims to share lessons learned and good practice that countries have put in place to mitigate the challenges. Executive summary Key findings This document outlines the key challenges

2021 European Centre for Disease Prevention and Control - Covid-19 Guidance

12. What is known about the risk of transmission of COVID-19 within post-secondary institutions and the strategies to mitigate on-campus outbreaks?

What is known about the risk of transmission of COVID-19 within post-secondary institutions and the strategies to mitigate on-campus outbreaks? What is known about the risk of transmission of COVID-19 within post-secondary institutions and the strategies to mitigate on-campus outbreaks? | Covid-19 Rapid Review | National Collaborating Centre for Methods and Tools This browser does not support PDFs, or the PDF is too large to render. Please download the PDF:

2021 COVID-19 Rapid Evidence Service

13. NACI rapid response: recommended use of AstraZeneca COVID-19 vaccine in younger adults

NACI rapid response: recommended use of AstraZeneca COVID-19 vaccine in younger adults AstraZeneca COVID-19 vaccine use in younger adults: NACI recommendation - Canada.ca Language selection Search Search Canada.ca Search Menu Main Menu You are here: NACI rapid response: Recommended use of AstraZeneca COVID-19 vaccine in younger adults On this page Recommendation NACI recommends that AstraZeneca COVID-19 vaccine should not be used in adults under 55 years of age at this time while the safety (...) signal of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) following vaccination with AstraZeneca COVID-19 vaccine is investigated further. Summary of rationale Rare cases of serious blood clots, including cerebral venous sinus thrombosis, associated with thrombocytopenia have been recently reported in Europe following post-licensure use of AstraZeneca COVID-19 vaccine . Cases identified so far have been primarily in women under the age of 55 years; although cases in men have also been

2021 CPG Infobase

14. AstraZeneca COVID-19 Vaccine Statement

AstraZeneca COVID-19 Vaccine Statement 128 Halls Rd • Whitby, Ontario • L1P 1Y8 Tel: 647-528-8586 • Email: info@thrombosiscanada.ca AstraZeneca COVID-19 Vaccine Statement (Toronto, Ontario April 2, 2021) - Thrombosis Canada acknowledges the recommendation of the National Advisory Committee on Immunization (NACI) to suspend the administration of the AstraZeneca SARS-CoV-2 vaccine in patients under 55 years of age. [NACI Statement Link] Thrombosis Canada, alongside NACI and other healthcare

2021 Thrombosis Interest Group of Canada

15. COVID-19 vaccination and blood clotting

COVID-19 vaccination and blood clotting COVID-19 vaccination and blood clotting - GOV.UK Cookies on GOV.UK We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content from their services. Accept additional cookies Reject additional cookies You can at any time. Hide this message Show or hide search Search (...) on GOV.UK Search GOV.UK Menu Rules, guidance and support Guidance COVID-19 vaccination and blood clotting Information on the benefits and risks of the COVID-19 vaccination. From: Published: 7 April 2021 Last updated: 13 April 2021, Documents HTML Ref: PHE gateway number 2021701 . Please tell us what format you need. It will help us if you say what assistive technology you use. Details This guidance summarises the benefits and risks of the COVID-19 vaccination. Paper copies of this leaflet are available

2021 Public Health England

16. COVID-19 vaccination: blood clotting information for healthcare professionals

COVID-19 vaccination: blood clotting information for healthcare professionals COVID-19 vaccination: blood clotting information for healthcare professionals - GOV.UK Cookies on GOV.UK We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content from their services. Accept additional cookies Reject additional (...) cookies You can at any time. Hide this message Show or hide search Search on GOV.UK Search GOV.UK Menu Rules, guidance and support Guidance COVID-19 vaccination: blood clotting information for healthcare professionals Information for healthcare professionals on blood clotting following COVID-19 vaccination. From: Published: 7 April 2021 Last updated: 9 April 2021, Documents HTML Ref: PHE gateway number 2021700 . Please tell us what format you need. It will help us if you say what assistive technology

2021 Public Health England

17. Managing the long-term effects of COVID-19

Managing the long-term effects of COVID-19 Managing the long-term effects of COVID-19 National guidance for identification, assessment and management Published: 18 December 2020 SIGN161Scottish Intercollegiate Guidelines Network Gyle Square, 1 South Gyle Crescent Edinburgh EH12 9EB www.sign.ac.uk First published December 2020 978-1-909103-83-2 Citation text Scottish Intercollegiate Guidelines Network (SIGN). Managing the long-term effects of COVID-19. Edinburgh: SIGN; 2020. (SIGN publication (...) no. 161). [December 2020]. Available from URL: http://www.sign.ac.ukContents 1 Introduction 1 1.1 The need for a guideline 1 1.2 Remit of the guideline 1 1.3 Terms used in the guideline 2 2 Identifying people with ongoing symptomatic COVID-19 or post-COVID-19 syndrome 4 2.1 Providing information 4 2.2 Identification 5 3 Assessing people with new or ongoing symptoms after acute COVID-19 8 3.1 Person-centred assessment 8 3.2 Symptoms and signs 9 4 Investigations and referral 10 4.1 Urgent referral 10

2021 SIGN

18. Progesterone in addition to standard of care versus standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19: a randomized, controlled pilot trial Full Text available with Trip Pro

Progesterone in addition to standard of care versus standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19: a randomized, controlled pilot trial CDEI - Progesterone in addition to standard of care versus standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19 — CDEI Open Menu Close Menu Open Menu Close Menu Mar 23 Written By Citation: Ghandehari, S. , Matusov, Y., Pepkowitz, S., Stein, D., Kaderi, T., Narayanan, D (...) ., ... & Lewis, M. (2021). Progesterone in addition to standard of care versus standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19: a randomized, controlled pilot trial. Chest . DOI: Clinical trials link: Journal impact factor: 8.308 (Chest) Full PICO and Limitations in text: Population: 42 male patients, aged 18+, with moderate-severe rRT-PCR confirmed SARS-CoV-2 infection and are hypoxemic with SaO2 < 94% and were receiving supplemental oxygen. Intervention

2021 Covid-19 Drug Evidence Initiative

19. Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial Full Text available with Trip Pro

Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial CDEI - Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial — CDEI Open Menu Close Menu Open Menu Close Menu Apr 1 Written By Citation: Murai, I. H. , Fernandes, A. L., Sales, L. P., Pinto, A. J., Goessler, K. F., Duran, C. S., ... & Pereira, R. M. (2021). Effect (...) of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: a randomized clinical trial. JAMA , 325(11), 1053-1060. DOI: Clinical trials link: Journal impact factor: 45.540 (JAMA) Full PICO and Limitations in text: Population: 240 adult patients ( > 18 years old) with moderate to severe SARS-CoV-2 confirmed via PCR testing or CT scan. Intervention and Comparator Intervention: 120 patients. Single dose of Vitamin D3 (200 000IU) dissolved in 10-mL peanut oil

2021 Covid-19 Drug Evidence Initiative

20. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis Full Text available with Trip Pro

Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) are temporarily unavailable. COVID-19 Information Show account info Close Account Logged in as: username Search: Search Save Email Send to Display options Display options Format Save citation to file Format: Create file Cancel Email citation Subject: 1 selected item: 33787911 - PubMed To: Format: MeSH and other data Send email Cancel Add to Collections Create a new collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your

2021 EvidenceUpdates